We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.60 | 111,474 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 9.40 | 9.80 | 9.60 | 9.60 | 9.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.44 | 89.07M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:10:57 | O | 10,833 | 9.518 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Presenting at the Annual Immuno-Oncology Summit |
| 16/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Block Listing Six Monthly Return |
| 03/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Employee exercise of share options |
| 02/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Scancell to Present at 2024 AACR Annual Meeting |
| 28/3/2024 | 13:21 | UK RNS | Scancell Holdings Plc Scancell Appoints WG as Joint Broker |
| 26/3/2024 | 14:00 | ALNC |  Scancell doses first patient in melanoma-focused trials |
| 26/3/2024 | 12:22 | UK RNS | Scancell Holdings Plc First iSCIB1+ patient dosed |
| 14/3/2024 | 11:17 | UK RNS | Scancell Holdings Plc Appointment of Sath Nirmalananthan to the Board |
| 12/3/2024 | 07:00 | UK RNS | Scancell Holdings Plc Scancell Attendance at Upcoming Conferences |
| 04/3/2024 | 07:00 | UK RNS | Scancell Holdings Plc Presenting at Next-Gen Immuno-Oncology Conference |
Scancell (SCLP) Share Charts1 Year Scancell Chart |
|
1 Month Scancell Chart |
Intraday Scancell Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/4/2024 | 23:44 | Scancell - Pot of Gold or POS? | 7,964 |
| 24/4/2024 | 11:01 | Scancell investors thread (litter free) | 399 |
| 17/1/2024 | 14:12 | Scancell for investors (inanaco free thread) | 235 |
| 09/12/2023 | 09:53 | Using immunology to fight cancer. | 57,587 |
| 01/12/2023 | 15:26 | Scancell - BS free thread | 2 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:10:57 | 9.52 | 10,833 | 1,031.08 | O |
| 13:08:11 | 9.52 | 3,000 | 285.54 | O |
| 10:50:33 | 9.43 | 1,000 | 94.26 | O |
| 10:41:12 | 9.52 | 105 | 9.99 | O |
| 10:26:00 | 9.52 | 5,253 | 499.98 | O |
| Top Posts |
|---|
Posted at 24/4/2024 09:20 by Scancell Daily Update Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.60p.Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £89,070,718. Scancell has a price to earnings ratio (PE ratio) of -7.44. This morning SCLP shares opened at 9.60p |
Posted at 18/4/2024 15:54 by marcusl2 18 April 2024Stifel notes that Scancell is currently at a compelling point for investment, with high expectations for the upcoming data release and a significant probability of continued success in its clinical trials. Reiterating its 'buy' advice and 30p a share price target, the bank said: "We continue to see significant value in Scancell's highly innovative approach to cancer vaccine development. "We see the next 12 months as a potentially transformative period for the business and view Scancell as an attractive investment at these levels." In afternoon trading the shares were marking time at 9.4p. |
Posted at 15/4/2024 11:05 by inanaco Glymabs was a spin off from the University as such Scancell seems to get a look in at what they develop and is in a position to transition them to the clinicas further research gets developed we clearly are in the best position bearing in mind that early research eats capital and is very high risk, which is why you need CRUK etc grant funding only moditope was discovered in house the rest developed further in house glymabs and immunobody discovered by Lindy team but working for the UNI if Scancell was to pay Lindy true worth ......... we would be skint ! what would GSK pay ? or even BioNtech we get clouded by the low share price ....... emptyend Posts: 544 Price: 10.10 Strong Buy RE: Probing the expression and adhesion of glycans involved in Helicobacter pylori infectionToday 06:57 This is actually a piece I find a bit concerning as a shareholder. It renews lingering questions in my mind about whether shareholder value is front and centre in the company’s activities, or whether the company is just a bolt-on to a venture which is publicly-funded pure science, being pursued for its own sake. Of couse there is a symbiosis here, but the company itself should be ENTIRELY focused on developing intellectual property and monetising it for the benefit of its shareholders. I’d like to think we would get RNSs soon that prove that is the focus, and not the science alone….. |
Posted at 11/4/2024 16:17 by inanaco interesting .......... moans about the flat share price but wont buy any !!best part has been making other investments apparently where returns will be greater/quicker future tense ......... and is apparently a "scientist" in this area then must appreciate that trial results = gains/losses along with patents and potential deals on preclinical assets already discussed seems a moody investor .... he should know Bio is a slow cook even with GENMABs cash mountain it takes time Burble Posts: 1,084 Price: 9.85 No Opinion RE: After AACR . . .Today 14:34 Dracula, I've slowly been averaging down over the years with a drip feed of purchases whenever I've had some spare cash. Still slightly underwater but it's not a crazy amount that it needs to climb to get back into a small profit. I'm hoping to hold out for when it does rise, but I've stopped making any major purchases as I feel there are other opportunities to invest in other companies where the returns will be greater/quicker than locking more money up here. |
Posted at 11/4/2024 08:29 by 2tyke Wasn't being rude.And I appreciate that most PI's don't understand how stock prices move and what drives them. My point is really this: When posters constantly expect share price moves based on outside events and RNS's....(only to discover that the polar opposite tends to happen). Why don't they consider that the problem is actually that their own 'premise' is wrong...and it's not the actual market which is wrong in not appreciating their fave stock ? There are no secrets about this company, every thing they are working on is well known to the scientific community. The stock, as with every stock, is only casually related to the company, and driven by the fear and greed patterns of traders as they try to profit or mitigate loss. SP's are controlled by the active traders, not the big holders. Most active traders are where the big profits are currently in crypto. Issues with lack of interest fall in price under 'their own weight'. A stock doesn't need volume to fall heavily. Just lack of interest...that's all. |
Posted at 10/4/2024 22:06 by 2tyke Well it turned out that the Q2 2024 share price was 10p- and not 40p+As usual, the scientific posters were quite wrong in their expectations. So they resort to the usual nonsense comments like 'under the radar'...lol. What they really mean is that 'they' don't understand the stock market. Oh...'it's obviously under-valued' they say...lol Try 'over-valued' that's why the price is dropping and not rising. PRICE is ALWAYS correct. It is agreed by both the buyers and the sellers. What the dreamers think is quite irrelevant. |
Posted at 09/4/2024 12:50 by inanaco How Does Privatization Work?Taking a public company private is relatively straightforward and typically involves fewer regulatory hurdles than private-to-public transitions. A private group will tender an offer for a company's shares and stipulate the price it is willing to pay. Typically, it's a premium over the current market price. If a majority of voting shareholders accept, the bidder pays the consenting shareholders the purchase price for every share they own. For example, if a shareholder owns 100 shares and the buyer offers $26 per share, the shareholder receives $2,600 for relinquishing their position and ownership in the company. This situation often favors shareholders due to the aforementioned premium. |
Posted at 03/2/2024 19:33 by chilltime On the point of a low share price versus our perception of where we think it should be, Lindy perks up my interest there.Various public companies can irrationally go ballistic on their share price based on hype, being the in thing catching market attention. In the Pharma world it's been the immunotherapy PD1 scene. Antibodies that unmask cancer cells to allow our immune systems to go on the attack and destroy them. Scancell are in the world of the a super boost for the attack with Scib. So it seems nailed on, with positive results that vaccines will become a very hot topic to combine with other treatments. Given the it's all about money, those with a patent cliff would seek any means to extend patents and dominate the market. Hence Lindy points to another company in the sector which she hopes has good results (due in a couple of months) as those results would put companies like Scancell in the spotlight. |
Posted at 31/1/2024 18:11 by markingtime 33p per share, based on "overly conservative" assumptions?Its a damned good job we have some large, well-informed, shareholders because (if Lindy's comments are anywhere near accurate) there must be a high chance of attracting a bidder against a background of a share price that is simply wrong. I'll be surprised if the share price is below 33p by year end (a market cap of about £340mn) |
Posted at 07/12/2023 13:37 by inanaco mia .... add the adjuvant resected market as well ............scancells product will work just as well at this stage as later stage ... its the same cancer after all miavoce Posts: 610 Price: 11.75 No Opinion ISCIB1+ - What is it worth ?Today 13:16 In somewhere between 12 and 18 months Scancell are likely to have enough data to convince big pharma that iSCIB1+ is sufficiently effective to make it worth licensing. So, what will big pharma have to pay and what will Scancell be worth. The market for iSCIB1+ in non resectable melanoma will be $4.5bn (3 x the SCIB1 market size), so let's say that big pharma estimate that can achieve annual sales of $2bn. How much would they have to pay Scancell to buy that future annual revenue stream - my guess would be $1bn up front plus $500m in milestones. They would also need to give a significant royalty to Scancell given the fact that the risk of failure will be low - my guess would be 15%. So, in 2025 Scancell might receive $1bn with the expectation of a further $500m over the following 2-3 years. This would certain push the share price towards the £1 mark irrespective of whatever else may be happening with our other products. Obviously the share price isn't going to stay at 12p until the deal is done - the progressive build up of positive data will make a deal more and more likely and the share price will rise in anticipation (not withstanding what may also be happening - e.g. trial data, deals - with our other products). The real kicker comes in later however when the royalty stream builds. 15% of $2bn is $300m of pure profit for Scancell each year. Based on a PE ratio of just 10 this would give Scancell a valuation of $3bn or around £2 per share and there may also be a decent dividend. And this is just for iSCIB1+ ! As trials progress and deals are done for other products they will only add to the valuation. |
Posted at 01/12/2023 10:05 by ih_486726 But the existing major investors already agreed to participate. A higher placing offer would change nothing for then except the company would issue fewer shares. As for the £2M to be raised from existing and new smaller shareholders, why would you prefer to be more diluted (most of the shares went to the big guys) and buy at 11p with the share price currently at that level, than buying at 14p also with the share price at that level. Plus the positivity a placing slightly above the current share price wouod create.Again there might be good reason for this, I just don't get it :/ |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
